NCT06531837

Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury

Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury: an Exploratory, Interventional, Non-randomized Controlled Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The diagnosis of chronic pain currently lacks objective and quantifiable biomarkers. This study aims to observe the EEG characteristics of patients with chronic pain following spinal cord injury and subsequently administer analgesic interventions with remifentanil, esketamine, flurbiprofen, and spinal cord stimulation. The correlation between EEG features and pain intensity will be examined. The research aims to advance the objectification of chronic pain diagnosis and treatment.

Conditions

• Chronic Pain

Interventions

Type	Name	Description
DRUG	Esketamine(Continuous infusion)	Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
DRUG	Remifentanil (Target-Controlled Infusion)	The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
DRUG	Flurbiprofen (Single intravenous injection)	Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
DEVICE	Spinal Cord Stimulation	Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.
OTHER	No intervention	Collect resting-state EEG data and NRS scores.

Timeline

• Start date: 2024-08-25
• Primary completion: 2026-01-31
• Completion: 2026-02-28
• First posted: 2024-08-01
• Last updated: 2024-08-13

Locations

1 site across 1 country: China